Vergnenegre Alain

Summary

Affiliation: CHU Dupuytren
Country: France

Publications

  1. ncbi [The payer, the T2A pathway, the physician, the patient: the exemple of thoracic oncology]
    A Vergnenegre
    Service de l Information Médicale et de l Evaluation, Hopital du Cluzeau, Limoges Cedex, France
    Rev Mal Respir 24:6S216-21. 2007
  2. doi Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study
    Alain Vergnenegre
    Service de Pathologie Respiratoire, CHU, Limoges
    J Thorac Oncol 6:161-8. 2011
  3. doi Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC
    Alain Vergnenegre
    Thoracic Oncological Unit, Limoges University Hospital, France Electronic address
    J Thorac Oncol 11:801-7. 2016
  4. doi How many drugs in the maintenance setting for non-small-cell lung cancer? For what benefit?
    Alain Vergnenegre
    Service de Pathologie Respiratoire CHU Dupuytren, Hopital du Cluzeau, 87042 Limoges Cedex, France
    Ann Palliat Med 2:170-2. 2013
  5. pmc Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
    Isabelle Borget
    Etudes et Recherche en Economie de la Santé, Service de biostatistique et d épidémiologie, Institut Gustave Roussy, 114, rue Edouard Vaillant, 94805 Villejuif, Cedex, France
    BMC Cancer 14:953. 2014
  6. pmc Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents
    A Vergnenegre
    Service de Pathologie Respiratoire et d Allergologie, CHU Dupuytren, Limoges, France INSERM, U707, Paris, France
    Clinicoecon Outcomes Res 5:137-41. 2013
  7. pmc Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
    Alain Vergnenegre
    Department of Pneumology, Hopital du Cluzeau, Limoges, France
    Clinicoecon Outcomes Res 4:31-7. 2012
  8. doi Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study)
    Alain Vergnenegre
    Chest Department of Limoges, France Electronic address
    Lung Cancer 82:353-7. 2013
  9. pmc Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)
    Christos Chouaid
    AP HP Hôpital St Antoine, AP HP, UMPC, Paris, France
    BMC Cancer 12:301. 2012
  10. doi [Supportive, palliative care in lung cancer]
    A Vergnenegre
    Service de Pathologie Respiratoire, Hopital du Cluzeau, CHU de Limoges, 23, avenue D Larrey, 87042 Limoges Cedex, France
    Rev Mal Respir 30:137-41. 2013

Detail Information

Publications47

  1. ncbi [The payer, the T2A pathway, the physician, the patient: the exemple of thoracic oncology]
    A Vergnenegre
    Service de l Information Médicale et de l Evaluation, Hopital du Cluzeau, Limoges Cedex, France
    Rev Mal Respir 24:6S216-21. 2007
    ..For a few years, the French health system has implemented a lot of reforms which have consequences on patients' management, particularly in oncology...
  2. doi Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study
    Alain Vergnenegre
    Service de Pathologie Respiratoire, CHU, Limoges
    J Thorac Oncol 6:161-8. 2011
    ..The objective of this phase III, randomized, multicenter, prospective study was to compare the cost-effectiveness of docetaxel and pemetrexed, two widely used drugs...
  3. doi Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC
    Alain Vergnenegre
    Thoracic Oncological Unit, Limoges University Hospital, France Electronic address
    J Thorac Oncol 11:801-7. 2016
    ....
  4. doi How many drugs in the maintenance setting for non-small-cell lung cancer? For what benefit?
    Alain Vergnenegre
    Service de Pathologie Respiratoire CHU Dupuytren, Hopital du Cluzeau, 87042 Limoges Cedex, France
    Ann Palliat Med 2:170-2. 2013
    ..Before a transfer into clinical practices and guidelines, new data on economic analyses (the cost effectiveness ratio was very high among specific studies) and quality of life are mandatory. ..
  5. pmc Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
    Isabelle Borget
    Etudes et Recherche en Economie de la Santé, Service de biostatistique et d épidémiologie, Institut Gustave Roussy, 114, rue Edouard Vaillant, 94805 Villejuif, Cedex, France
    BMC Cancer 14:953. 2014
    ..This analysis was undertaken to assess the incremental cost-effectiveness ratio (ICER) of these strategies for the global population and pre-specified subgroups...
  6. pmc Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents
    A Vergnenegre
    Service de Pathologie Respiratoire et d Allergologie, CHU Dupuytren, Limoges, France INSERM, U707, Paris, France
    Clinicoecon Outcomes Res 5:137-41. 2013
    ..The incidence of lung cancer and the cost of drug treatment have increased dramatically in the last decade. This article examines the costs of new target agents, such as tyrosine kinase inhibitors (TKIs) and anti-angiogenic drugs...
  7. pmc Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
    Alain Vergnenegre
    Department of Pneumology, Hopital du Cluzeau, Limoges, France
    Clinicoecon Outcomes Res 4:31-7. 2012
    ..We aimed to estimate the incremental cost-effectiveness of erlotinib 150 mg/day versus best supportive care when used as first-line maintenance therapy for patients with locally advanced or metastatic NSCLC and stable disease...
  8. doi Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study)
    Alain Vergnenegre
    Chest Department of Limoges, France Electronic address
    Lung Cancer 82:353-7. 2013
    ..The objective of this study was to examine, in a prospective cohort of advanced NSCLC patients, PC use and factors associated with early (≤3 months after diagnosis) PC initiation...
  9. pmc Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)
    Christos Chouaid
    AP HP Hôpital St Antoine, AP HP, UMPC, Paris, France
    BMC Cancer 12:301. 2012
    ....
  10. doi [Supportive, palliative care in lung cancer]
    A Vergnenegre
    Service de Pathologie Respiratoire, Hopital du Cluzeau, CHU de Limoges, 23, avenue D Larrey, 87042 Limoges Cedex, France
    Rev Mal Respir 30:137-41. 2013
    ..Despite recent advances, the prognosis of lung cancer (LC) remains poor and justifies the early introduction of palliative care (PC) and supportive care (SC). The objective of this paper is to describe the published data in this field...
  11. ncbi [Economic analysis of home based versus hospital outpatient chemotherapy in stage IV non small cell lung cancer]
    A Vergnenegre
    Service de l Information Médicale et de l Evaluation, Hopital du Cluzeau, CHU de Limoges, France
    Rev Mal Respir 23:255-63. 2006
    ..French law and government decisions have induced new development for home base treatments. The objective was to compare cost of home base chemotherapy (HBC) versus outpatient infusions, for non small cell lung cancer (NSCLC)...
  12. ncbi [How to take into account the cost effectiveness parameters in the management of bronchial carcinoma?]
    A Vergnenegre
    Service de l Information Médicale et de l Evaluation, Hôpital du Cluzeau 87042 Limoges Cedex
    Rev Mal Respir 23:10S17-10S20. 2006
  13. ncbi [Stage IV non-small cell lung cancer. Duration of chemotherapy for locally advanced non small cell lung cancers]
    A Vergnenegre
    Service de Pathologie Respiratoire, Hopital du Cluzeau, CHU Dupyutren, Limoges, France
    Rev Mal Respir 23:16S72-16S77. 2006
    ..Optimal duration of first line chemotherapy for non surgical non small cell lung cancer (NSCLC) is still debated. It concerns the length of initial chemotherapy and the use of maintenance treatments...
  14. ncbi [Stage IV NSCLC. Economic analysis in lung cancers]
    A Vergnenegre
    Service de l Information Médicale et de l Evaluation, Service de Pneumologie, Hopital du Cluzeau, CHU Limoges, France
    Rev Mal Respir 25:3S127-37. 2008
    ..To explain the help of economic analyses in the understanding of lung cancer (LC) management with a description of the quality of selected papers...
  15. doi A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin
    Alain Vergnenegre
    Service de Pathologie Respiratoire, CHU, Limoges, France
    J Thorac Oncol 4:364-70. 2009
    ..The objective of the trial was to evaluate a switch to a different dual-agent chemotherapy...
  16. doi Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study
    A Vergnenegre
    Service de Pneumologie, Hopital du Cluzeau, et Unité de Recherche Clinique et Biostatistique, CHU Limoges, France
    Lung Cancer 74:264-7. 2011
    ..Erlotinib therapy for non small-cell lung cancer (NSCLC) has mainly been evaluated in randomized trials...
  17. ncbi [Inhaled corticosteroids in asthma: a medico-economic analysis of clinical trials]
    A Vergnenegre
    Hopital du Cluzeau, 23 avenue D Larrey, Limoges Cedex, France
    Rev Mal Respir 25:375-89. 2008
    ..The objective of this study was to undertake an analysis of the published literature of medico-economic trials of the use of inhaled corticosteroids...
  18. ncbi Economic analyses and lung cancer
    A Vergnenegre
    Service de l Information Médicale et de l Evaluation, Service de Pneumologie, Hopital Universitaire du Cluzeau, 23, avenue Dominique Larrey, 87042 Limoges, France
    Monaldi Arch Chest Dis 56:336-43. 2001
    ..These methods, which provide complementary data for clinicians when making decisions on therapeutic options, will be adopted more widely in coming years...
  19. pmc Economics of the clinical management of lung cancer in France: an analysis using a Markov model
    C Chouaid
    Service de Pneumologie, Hopital St Antoine, 184 rue du Fbg St Antoine, Paris Cedex 12 75571, France
    Br J Cancer 90:397-402. 2004
    ..In conclusion, this model provides a robust economic analysis of the cost of lung cancer management, and will be useful for assessing the economic consequences of future changes in patient management...
  20. doi A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC
    H Lecaer
    Service de Pneumologie, CH de Draguignan, France
    Lung Cancer 77:97-103. 2012
    ....
  21. doi [A phase II study of weekly cisplatine plus oral vinorelbine with concomittant radiotherapy in non-dependent elderly patients with localized inoperable non small cell lung carcinoma (Essai GFPC 08-06, Raccosa)]
    C Locher
    Unité de Chimiothérapie Ambulatoire, Service de Pneumologie, Centre Hospitalier de Meaux, 6 8 rue Saint Fiacre, 77100 Meaux, France
    Rev Mal Respir 28:58-65. 2011
    ..A phase II study of weekly cisplatine plus oral vinorelbine with concomittant radiotherapy in non-dependent elderly patients with localized inoperable non small cell lung carcinoma (Essai GFPC 08-06, Raccosa)...
  22. ncbi Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01)
    A Vergnenegre
    CHU Limoges, France
    Ann Oncol 17:1269-74. 2006
    ..We conducted an economic analysis of a phase III clinical trial comparing sequential radiochemotherapy (RT-CT) with concurrent RT-CT in patients with locally advanced non-small-cell lung cancer...
  23. ncbi [The cost components of the management strategies for lung cancer in France]
    A Vergnenegre
    Service de l Information Médicale et de l Evaluation, Service de Pneumologie, Hôpital Cluzeau, Limoges, France
    Rev Mal Respir 21:501-10. 2004
    ..To evaluate the average cost of therapeutic strategies for the management of lung cancer in relation to histological type and diagnostic staging and of the individual components of the management strategy...
  24. ncbi [Investigation of allergic reactions to platinum salts]
    F Touraine
    Service de Pathologie Respiratoire, CHU de Limoges, Limoges, France
    Rev Mal Respir 23:458-62. 2006
    ..Investigation by skin tests and flow cytometry confirmed the clinical diagnosis in both cases...
  25. ncbi Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC)
    A Vergnenegre
    CHU de Limoges, Service de l Information Médicale et de l Evaluation, Service de Pathologie Respiratoire et d Allergologie, Hopital du Cluzeau, CHU Dupuytren, 87042 Limoges Cedex, France
    Lung Cancer 47:395-404. 2005
    ..The most satisfactory treatment for patients with locally advanced non-small-cell lung cancer (NSCLC) is combination chemotherapy-radiotherapy (CT-RT). The optimal treatment modalities remain to be determined...
  26. ncbi [Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer]
    C Chouaid
    Service de Pneumologie, Hopital Saint Antoine, APHP, Paris, France
    Rev Mal Respir 25:1096-103. 2008
    ..This study examined care consumption and management costs among patients who received second- or third-line oral erlotinib therapy for non small-cell lung cancer (NSCLC)...
  27. ncbi Randomized follow-up study of resected NSCLC patients: conventional versus 18F-DG coincidence imaging
    J Monteil
    Departement of Nuclear Medicine, University Hospital, Limoges, 87042 Limoges Cedex, France
    Anticancer Res 30:3811-6. 2010
    ..CDET imaging was more expensive. CDET imaging provides earlier detection of recurrence, but does not modify survival outcome. Further studies are necessary to demonstrate the impact, if any, of 18-FDG imaging...
  28. ncbi [The costs of asthma in France: an economic analysis by a Markov model]
    C Chouaid
    Service de Pneumologie, Hopital Saint Antoine, Assistante Publique Hôpitaux de Paris, France
    Rev Mal Respir 21:493-9. 2004
    ..To develop a medico-economic model to identify the mean annual cost of a patient with asthma together with the components of the cost and the consequences of different modalities of management (out-patient and in-patient)...
  29. ncbi [Cost-effectiveness analysis: a readers' guide]
    A Vergnenegre
    Service de l Information Médicale et de l Evaluation, Hopital du Cluzeau, CHU Dupuytren, Limoges, France
    Rev Mal Respir 21:S47-55. 2004
  30. ncbi [What is a non-parametric test?]
    F Dalmay
    UF de Recherche Clinique et Biostatistique, Service de l Information Médicale et de l Evaluation, Centre Hospitalier Universitaire, Hopital du Cluzeau, Limoges, France
    Rev Mal Respir 20:955-8. 2003
  31. ncbi [Chemotherapy at home: what implications, what concerns?]
    A Vergnenegre
    Service de Pathologie Respiratoire, Service de l Information Médicale et de l Evaluation, CHU, 2 Avenue Martin Luther King, 87000 Limoges, France
    Rev Pneumol Clin 60:4S61-4S64. 2004
  32. ncbi [Cost-effectiveness analysis: a reader's guide]
    A Vergnenegre
    Service de l Information Médicale et de l Evaluation, Hopital du Cluzeau, CHU Dupuytren, Limoges Cedex, France
    Rev Mal Respir 20:116-25. 2003
    ..This article is devoted to the critical appraisal of cost-effectiveness analysis...
  33. doi [The Lady Windermere syndrome: clinical and bacteriological data and progress in seven cases]
    F Bonnaud
    Service de Pneumologie et d Allergologie, Hopital Universitaire du Cluzeau, 23 rue Dominique Larrey, Limoges, France
    Rev Mal Respir 29:714-8. 2012
    ....
  34. ncbi [Radon and domestic exposure]
    B Melloni
    Service de Pathologie Respiratoire et d Allergologie, Hopital Universitaire du Cluzeau, CHU Limoges
    Rev Mal Respir 17:1061-71. 2000
    ..Scientific knowledge of effects of low levels of exposure to radon and the role of cigarette smoking, as a combined factor, must be studied. Smoking and radon probably interact in a multiplicative fashion...
  35. ncbi Variability of ankle-arm index in general population according to its mode of calculation
    V Aboyans
    Departments of Cardiovascular Surgery and Angiology, Dupuytren University Hospital, Limoges, France
    Int Angiol 21:237-43. 2002
    ..We aimed to study the variance of the different measurements required to calculate the AAI according to different formulas, in order to find out the best way of AAI calculation, based on its lesser variability...
  36. ncbi [Tools for assessing healthcare delivery]
    A Vergnenegre
    Service de l Information Médicale et de l Evaluation, Service de Pathologie Respiratoire et d Allergologie, Hopital du Cluzeau, CHU de Limoges, France
    Rev Mal Respir 23:3S47-60. 2006
    ..Assessing the quality of care has become an essential part of the medical process. In France, the Professional Practice Evaluation requires a sound knowledge of these techniques...
  37. ncbi [Value of 18FDG-CDET in the evaluation of operable bronchial cancer]
    B Melloni
    Service de Pathologie Respiratoire et d Allergologie, Universitaire de Limoges
    Rev Mal Respir 18:599-606. 2001
    ..In addition, FDG CDET shows high accuracy for the detectability of pulmonary lesions with a diameter at least 2 cm and the evaluation of lymph node in NSCLC...
  38. ncbi [Evaluation of respiratory intensive care units at pneumology services]
    A Vergnenegre
    Service de l Information Médicale et de l Evaluation, Hopital Universitaire du Cluzeau, 87042 Limoges
    Rev Mal Respir 18:507-16. 2001
    ..We present here examples issuing for the ICU of the Hôtel-Dieu Hospital in Paris. The results show that non-specific national indicators, in combination with other indicators specific for respiratory ICU, provide appropriate audit data...
  39. ncbi [Clinical practice guidelines: a reader's guide]
    A Vergnenegre
    Service de l Information Médicale et de l Evaluation, Service de Pathologie Respiratoire, CHU de Limoges, Limoges, France
    Rev Mal Respir 20:920-7. 2003
    ..This article is devoted to the critical appraisal of clinical guidelines...
  40. ncbi [Logistic regression]
    P M Preux
    Service de l Information Médicale et de l Evaluation, UF de Recherche Clinique et Biostatistique, Hopital du Cluzeau, Limoges, France
    Rev Mal Respir 22:159-62. 2005
  41. ncbi [Impact of economic criteria on clinical decisions]
    A Vergnenegre
    Service de Pneumologie, CHU Limoges, 23, avenue D Larrey, 87042 Limoges
    Rev Pneumol Clin 59:S59-62. 2003
  42. ncbi [What is a parametric test?]
    P M Preux
    UF de Recherche Clinique et Biostatistique, Service de l Information Médicale et de l Evaluation, Centre Hospitalier Universitaire, Hopital du Cluzeau, Limoges, France
    Rev Mal Respir 20:952-4. 2003
  43. ncbi [Age and management decisions in patients with primary lung cancer]
    S Yonnet
    Registre Général des Cancers en Limousin, Limoges, France
    Rev Mal Respir 25:295-302. 2008
    ..Our objective was to evaluate the role of age in the management of patients suffering from primary lung cancer seen in the department of respiratory diseases of the Limoges regional teaching hospital between 2002 and 2004...
  44. ncbi [Clinical guidelines: a readers' guide]
    A Vergnenegre
    Service de l Information Médicale et de l Evaluation, Hopital du Cluzeau, CHU Dupuytren, Limoges, France
    Rev Mal Respir 21:S56-62. 2004
  45. doi [Geriatric assessment contribution to treatment decision-making in thoracic oncology]
    V Aliamus
    Registre général des cancers du Limousin, SIME, Hopital du Cluzeau, CHU Dupuytren, 23, avenue Dominique Larrey, 87042 Limoges Cedex, France
    Rev Mal Respir 28:1124-30. 2011
    ..Lung cancer is a frequently occurring disease among elderly people. The objective of this study was to search for a relationship between multimodal geriatric assessment and a decision-making in the treatment of patients with this condition...
  46. ncbi [Lung cancer and indoor environment]
    F Bonnaud
    Service de Pathologie Respiratoire, Hopital Universitaire du Cluzeau, Limoges, France
    Rev Mal Respir 24:248-51. 2007
  47. ncbi [Quality of medical records in the "Medical Information System Program": application of the lot quality assurance sampling method]
    M L Laroche
    Service de l Information Médicale et de l Evaluation, Hopital du Cluzeau, 23, avenue Dominique Larrey, 87042 Limoges Cedex
    Rev Epidemiol Sante Publique 50:433-9. 2002
    ..The aim of this study was to validate a new method of quality control of medical records of the "Medicalisation of Information System Program" (P.M.S.I.) in Limoges university hospital...